Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

161.65
Net Asset Value
-1.15%
1 Day
+22.30%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.81%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month-1.98% 3 years+6.98%
3 months+2.65% 5 years+18.86%
1 year+22.99% Since inception+19.72%
Data through --

Peer Comparisonvs. Health

 FTDZXCategory
Performance 5-yr return+18.86%+16.79%
Expense ratio0.81%1.33%
Risk 5 year sharpe ratio0.831.10
Net assets$1.5B$3.1B
Average market cap$9.8B$30.9B
Average P/E--26.2
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$100,000.00
Minimum IRA investment--

Holdings

U.S. stock92.28%
Cash3.66%
International stock2.14%
Fixed income1.92%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
CELG Celgene9.97%
ALXN Alexion Pharmaceuticals Inc7.39%
INCY Incyte Corp5.86%
REGN Regeneron Pharmaceuticals5.57%
BIIB Biogen4.57%
GILD Gilead Sciences4.31%
ILMN Illumina Inc3.96%
CLVS Clovis Oncology Inc3.87%
TSRO TESARO Inc3.51%
VRTX Vertex Pharmaceuticals Inc3.48%